List of Cambia drug patents
Cambia is owned by Assertio.
Cambia contains Diclofenac Potassium.
Cambia has a total of 4 drug patents out of which 0 drug patents have expired.
Cambia was authorised for market use on 17 June, 2009.
Cambia is available in for solution;oral dosage forms.
Cambia can be used as acute treatment of migraine attacks with or without aura in adults.
The generics of Cambia are possible to be released after 16 June, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8097651 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
| US7759394 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927604 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
| US9827197 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
Drugs and Companies using DICLOFENAC POTASSIUM ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: FOR SOLUTION;ORAL
CAMBIA family patents
9
United States
5
European Union
3
Spain
3
China
2
Canada
1
Portugal
1
Turkey
1
Russia
1
Guatemala
1
Jordan
1
Brazil
1
New Zealand
1
Norway
1
Argentina
1
Mexico
1
Peru
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
South Africa
1
Poland
1
Australia
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic